McNamara Peter 4

4 · Tectonic Therapeutic, Inc. · Filed Mar 9, 2026

AI-generated summary of this filing

Updated Mar 9, 2026

Tectonic Therapeutic (TECX) CSO Peter McNamara Sells Shares, Exercises Options

What Happened

Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic (TECX), exercised stock options to acquire 2,715 shares (2,500 @ $2.38 and 215 @ $14.71; total cost reported ~$9,113) and sold a total of 6,262 shares in open‑market transactions (6,047 @ $30.00 = $181,410 and 215 @ $35.00 = $7,525; total proceeds ~$188,935). The exercises and sales occurred on March 6, 2026.
This activity involved option exercises (derivative transactions) followed by open‑market sales. Sales are typically routine liquidity events; purchases (option exercises) can be viewed as acquiring shares but here were performed as part of the same set of transactions.

Key Details

Transaction date: March 6, 2026; Form 4 filed March 9, 2026 (appears filed within required reporting window).
Exercise details acquired: 2,500 shares at $2.38 ($5,950) and 215 shares at $14.71 ($3,163) — total acquired 2,715 shares.
Sales details disposed: 6,047 shares at $30.00 ($181,410) and 215 shares at $35.00 ($7,525) — total sold 6,262 shares; combined sale proceeds ≈ $188,935.
Shares owned after transaction: Not specified in the provided filing excerpt.
Footnotes of interest:
- F1: These exercises and sales were executed under a Rule 10b5‑1 trading plan adopted Nov 14, 2025 (pre‑planned trades).
- F2/F4: Option grants referenced have multi‑year vesting schedules (vesting details provided in footnotes).
- F3: Some options were received in exchange for options related to a prior merger (see referenced June 24, 2024 Form 4).
Filing timeliness: Report filed March 9 for March 6 transactions — appears timely.

Context

The sequence (exercise of options and contemporaneous sales) suggests a common pattern where an insider exercises vested options and sells shares for liquidity or to cover exercise costs/taxes. The 10b5‑1 plan note indicates these trades were pre‑planned rather than opportunistic.
For retail investors: purchases (net buys) often carry more informational weight than routine sales; here the net effect is a larger sale than acquisition, and the trades were conducted under a pre‑arranged plan.

Form 4

Period: 2026-03-06

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-06$2.38/sh+2,500$5,950→ 61,332 total
Exercise/Conversion
Common Stock
[F1]
2026-03-06$14.71/sh+215$3,163→ 61,547 total
Sale
Common Stock
[F1]
2026-03-06$30.00/sh−6,047$181,410→ 55,500 total
Sale
Common Stock
[F1]
2026-03-06$35.00/sh−215$7,525→ 55,285 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
[F1][F3][F2]
2026-03-06−2,500→ 31,959 total
Exercise: $2.38Exp: 2031-06-27→ Common Stock (2,500 underlying)
Exercise/Conversion
Employee Stock Option (Right to Buy)
[F1][F4]
2026-03-06−215→ 8,045 total
Exercise: $14.71Exp: 2035-09-24→ Common Stock (215 underlying)

Footnotes (4)

[F1]These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025.
[F2]25% of the shares subject to the option vested on June 1, 2022; and the remainder of the shares subject to the option vest in 36 equal monthly installments with the final amount vesting on June 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
[F3]Received in exchange for a stock option to acquire 71,029 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml
[F4]The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Signature

/s/ Daniel Lochner, Attorney-in-Fact|2026-03-09

1 file